<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00936520</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00029830</org_study_id>
    <nct_id>NCT00936520</nct_id>
  </id_info>
  <brief_title>SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy</brief_title>
  <official_title>A Phase 1b, Randomized, Uncontrolled, Single-masked, Safety, Tolerability, and Pharmacokinetic Study of Multiple Doses of Three Different Concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution in Human Subjects Undergoing Elective Pars Plana Vitrectomy (PPV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SARcode Bioscience</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of&#xD;
      SAR 1118 within the anterior and posterior chamber of the eye and plasma in subjects&#xD;
      undergoing elective vitrectomy when treated with escalating concentrations of the study drug&#xD;
      for approximately 1 week.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SAR 1118 is a potent and selective small molecule lymphocyte function antigen-1 (LFA-1)&#xD;
      antagonist and may be therapeutically useful as a novel topical anti-inflammatory agent in a&#xD;
      wide variety of ocular inflammatory conditions including diabetic retinopathy and diabetic&#xD;
      macular edema. Recent evidence has demonstrated that topically delivered SAR 1118 ophthalmic&#xD;
      solution can be detected in the aqueous, vitreous, and retina 4 to 12 hours after dosing at&#xD;
      potentially therapeutic levels in animal models. However, the ability for the current sterile&#xD;
      ophthalmic formulation of SAR 1118 to penetrate in sufficiently high therapeutic&#xD;
      concentrations into the anterior and posterior chamber in humans is unknown.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Preliminary analysis showed little or no bioactivity.&#xD;
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome variable: frequency of ocular and non-ocular adverse events judged related to administration of SAR 1118 Ophthalmic Solution, or of inability to tolerate the medication.</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcome variable: concentrations of SAR 1118 in aqueous and vitreous on the day of vitrectomy.</measure>
    <time_frame>day 9</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetic Macular Edema (DME)</condition>
  <condition>Pars Plana Vitrectomy</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR 1118 dose 0.1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR 1118 dose 1.0%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR 1118 dose 5.0%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR 1118 0.1%</intervention_name>
    <description>Daily eye drops (twice daily, ~50 microliter [uL] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days</description>
    <arm_group_label>Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR 1118 1.0%</intervention_name>
    <description>Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days</description>
    <arm_group_label>Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR 1118 5.0%</intervention_name>
    <description>Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days</description>
    <arm_group_label>Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Human subjects meeting the following criteria will be enrolled:&#xD;
&#xD;
               -  Age ≥18 years&#xD;
&#xD;
               -  BCVA ≤20/40 in the study eye (BCVA measured at 4M ETDRS)&#xD;
&#xD;
               -  Male or female&#xD;
&#xD;
               -  Current non-smoker (last date of smoking should be at least 60 days before study&#xD;
                  enrollment)&#xD;
&#xD;
               -  Surgically eligible to undergo elective PPV including, but not limited to,&#xD;
                  epiretinal membrane, vitreomacular traction, macular holes, or retinal&#xD;
                  detachment. The elective surgery must be able to be scheduled at least 21 days in&#xD;
                  advance to allow time for screening and for initiation of study drugs.&#xD;
&#xD;
               -  Females must be non-pregnant, non-lactating, surgically sterile for at least 3&#xD;
                  months, post-menopausal for at least 1 years with follicle stimulating hormone&#xD;
                  (FSH) greater than or equal to 40 mIU/mL, or willing to use an approved method of&#xD;
                  contraception from 35 days prior to first study drug administration. Approved&#xD;
                  methods of contraception include: a non-hormonal intrauterine device (IUD) with&#xD;
                  spermicide, a female condom with spermicide, a diaphragm with spermicide, a&#xD;
                  cervical cap with spermicide, use of a condom with spermicide by sexual partner&#xD;
                  or sterile sexual partner.&#xD;
&#xD;
               -  Willing and able to provide written informed consent after the nature of the&#xD;
                  study has been explained, and prior to any research-related procedures.&#xD;
&#xD;
               -  Willing and able to comply with all study procedures including follow-up&#xD;
                  instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals not eligible to participate in this study include those who meet any of&#xD;
             the following criteria:&#xD;
&#xD;
               -  Vitreous hemorrhage&#xD;
&#xD;
               -  Active retinal detachment&#xD;
&#xD;
               -  Autoimmune disease of the anterior segment or posterior chamber including chronic&#xD;
                  keratoconjunctivitis sicca, uveitis, iritis/scleritis, blepharitis of either eye&#xD;
&#xD;
               -  Glaucoma requiring topical medications, infectious conjunctivitis, keratitis, or&#xD;
                  endophthalmitis of either eye&#xD;
&#xD;
               -  Prior vitrectomy or intraocular lens placement, within 90 days of Day 0&#xD;
&#xD;
               -  Previous intravitreal drug delivery administered in the study eye within the&#xD;
                  following time period of Day 0:&#xD;
&#xD;
                    -  Intravitreal steroid given ≤3 months&#xD;
&#xD;
                    -  Intravitreal vascular endothelial growth factor inhibitors given ≤2 months&#xD;
&#xD;
               -  Previous participation in any studies of investigational drugs within 1 month&#xD;
                  preceding Day 0&#xD;
&#xD;
               -  Any concurrent ophthalmic over-the-counter or topical ocular pharmaceutical&#xD;
                  within 30 days of Day 0 with the exception of saline tear lubricant.&#xD;
&#xD;
               -  History of malignancy, renal insufficiency, or hepatic insufficiency&#xD;
&#xD;
               -  Positive serum pregnancy test&#xD;
&#xD;
               -  Use of any oral, implantable, or injectable contraceptive within 30 days or 5&#xD;
                  half-lives of the contraceptive (whichever is longer) prior to first study drug&#xD;
                  administration; patients must refrain from these types of contraceptives during&#xD;
                  the treatment period and may resume the use of such contraceptives following the&#xD;
                  1-week observation period.&#xD;
&#xD;
               -  Any history of excessive alcohol (as judged by the Investigator) or illicit drug&#xD;
                  use/abuse&#xD;
&#xD;
               -  Consumption of any alcohol or any illicit drugs within one week of first study&#xD;
                  drug administration&#xD;
&#xD;
               -  Use of any tobacco or nicotine-containing products within 2 months prior to first&#xD;
                  study drug administration&#xD;
&#xD;
               -  Any laboratory abnormality considered clinically significant by the Investigators&#xD;
&#xD;
               -  Subjects with a hemoglobin &lt; 12.0 g/dL&#xD;
&#xD;
               -  Any clinically significant acute or chronic medical condition that would preclude&#xD;
                  participation in a clinical study&#xD;
&#xD;
               -  Any history of autoimmune disease, immunodeficiency disorder, positive HIV, acute&#xD;
                  hepatitis A (IgM positive), or hepatitis B, or C, or organ or bone marrow&#xD;
                  transplant&#xD;
&#xD;
               -  Participation in an ongoing investigational drug or medical device study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana V Do, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>July 9, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>DME</keyword>
  <keyword>Pars Plana Vitrectomy</keyword>
  <keyword>Ocular Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lifitegrast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

